Find clinical trials for Lymphoma in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma

Leukemia

Non-Hodgkin Lymphoma

Lymphoid Leukemia

Diffuse Large B-Cell Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Boston, MA, USA:

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not rec...

Enrolling

Indolent Non-hodgkin Lymphoma

Marginal Zone Lymphoma

Drug: Obinutuzumab

Drug: Glofitamab

Phase 2

Reid Merryman, MD

Boston, Massachusetts, United States and 1 other location

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ...

Enrolling

Refractory Plasmablastic Lymphoma

Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma

Drug: Belantamab Mafodotin

Phase 2

Jacob Soumerai, MD

Boston, Massachusetts, United States and 2 other locations

Axi-cel in CNS Lymphoma

therapy in treating relapsed/refractory central nervous system (CNS) lymphoma, systemic lymphoma with concurrent CNS lymphoma...

Active, not recruiting

Lymphoma Cns

Lymphoma

Drug: Cyclophosphamide

Biological: Axicabtagene Ciloleucel

Phase 1

Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 1 other location

Tisagenlecleucel In Primary CNS Lymphoma

In this study, is researching the safety of tisagenlecleucel in participants with primary central nervous system lymphoma. .-The name of the...

Active, not recruiting

Primary CNS Lymphoma

Relapsed Primary CNS Lymphoma

Biological: Tisagenlecleucel

Phase 1

Matthew J. Frigault, M.D.

Boston, Massachusetts, United States

Epcoritamab and Rituximab for First-line Follicular Lymphoma

of rituximab and epcoritamab is in treating patients with Follicular Lymphoma (FL) and who have not received other treatments for their lymphoma...

Enrolling

Low Grade Non-Hodgkin's Lymphoma, Adult

Follicular Lymphoma

Drug: Rituximab

Drug: Epcoritamab

Phase 2

Reid Merryman, MD

Boston, Massachusetts, United States

RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA

This research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma.The drugs invo...

Active, not recruiting

Follicular Lymphoma

Drug: Avelumab

Drug: PF04518600

Phase 1

Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 5 other locations

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of...

Active, not recruiting

Marginal Zone Lymphoma

Mantle Cell Lymphoma

Drug: imvotamab

Phase 1, Phase 2

IGM Biosciences

Boston, Massachusetts, United States and 26 other locations

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

Adult T-cell leukemia/lymphoma (ATLL) is a rare form of cancer found mostly among people from the Caribbean islands, Western Africa, Brazil,...

Active, not recruiting

Lymphoma

Adult T-Cell Leukemia/Lymphoma

Drug: CHEP

Drug: Brentuximab Vedotin

Phase 2

UNC Lineberger Comprehensive Cancer Center

Boston, Massachusetts, United States and 3 other locations

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy.This research is being...

Enrolling

Refractory Lymphoma

Lymphoma, B-Cell

Radiation: Adaptive Bridging Radiation Therapy (ABRT)

Mass General Brigham

Boston, Massachusetts, United States and 1 other location

DS-3201b in Participants With Lymphomas

DS-3201b is an experimental drug. It is not approved for regular use. It can only be used in clinical research.Adults with non-Hodgkin lymphoma...

Active, not recruiting

Lymphoma, Malignant

Non-hodgkin Lymphoma

Drug: DS-3201b

Phase 1